Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.

CONCLUSION: In recurrent ovarian cancer patients with expected suboptimal response to platinum, trabectedin + PLD may offer an active alternative, which differs from the first-line schedule, and may enhance the efficacy of subsequent platinum rechallenge. PMID: 30223694 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30223694?dopt=Abstract

Source: Expert Review of Anticancer Therapy - September 20, 2018 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research